



## Pharmacy Updates Coming Soon

### Changes for Specific J-Codes

Effective July 1, 2026, please see changes below for J3245 and J7340.

- J3245 Injection, tildrakizumab, 1 mg
  - It will transition to buy and bill for Commercial plans only.\*
  - It will continue to require prior authorization for members in:
    - HAP Medicare Advantage plans
    - HAP Commercial plans
    - HAP Qualified Health Plans (off-exchange)
  
- J7340 Carbidopa 5 mg/levodopa 20 mg enteral suspension
  - It will change to **not covered** under the medical benefit for HAP Commercial plans only. It may be covered under the member's prescription drug plan.

### Prescription Formulary Changes

Generic for Farxiga, **dapagliflozin**, is now available for your patients and covered at lower tier cost share than branded SGLT-2 products. This placement of generic supports dapagliflozin as a preferred SGLT-2 for members in:

- HAP Medicare Advantage plans
- HAP Commercial plans
- HAP Qualified Health plans (off-exchange)

\*Physician-administered drug is purchased by the provider/clinic upfront, administered to the patient, and then billed to the health plan for drug and administration.